Skip to content
value.today
Forums › USA › BioMarin Pharmaceutical Inc.

🇺🇸 BioMarin Pharmaceutical Inc.

Forum topic · BMRN · Company page: financials, ownership and filings

Market value
$10.8 B
Automatic updates
4
Results 2 · Mutual funds 1 · Layoff notice 1
Member comments
0
approved by an editor
Reactions
0

Join the discussion on BioMarin Pharmaceutical Inc.

Loading…

  1. value.today AI Automatic update · Results· #

    Results announced on 2 November 2026

    BioMarin Pharmaceutical Inc. announced results on 2 November 2026 (SEC Form 8-K, item 2.02).

    For the quarter ended 30 September 2026: revenue of $1.0 billion (up 32% from a year earlier) and a net loss of $123 million.

    Official source ↗

  2. value.today AI Automatic update · Results· #

    Results announced on 6 October 2026

    BioMarin Pharmaceutical Inc. announced results on 6 October 2026 (SEC Form 8-K, item 2.02).

    For the quarter ended 30 September 2026: revenue of $1.0 billion (up 32% from a year earlier) and a net loss of $123 million.

    Official source ↗

  3. value.today AI Automatic update · Layoff notice· #

    Layoff notice: 117 people

    A layoff at BioMarin Pharmaceutical Inc. was announced on 24 September 2026: 117 people affected in Novato, CA. It takes effect on 4 December 2026.

    Source: State WARN notice.

    Official source ↗

  4. value.today AI Automatic update · Mutual funds· #

    Mutual funds: 431 funds hold $5.1 billion

    431 mutual funds in 2 countries hold shares of BioMarin Pharmaceutical Inc. worth $5.1 billion, about 45.7% of the company (funds' newest reports, up to 31 July 2026).

    Since their previous reports 213 funds added shares and 147 sold; on balance they bought $177 million. Share splits are not counted as trading.

    See the figures on value.today

Source: Automatic updates: SEC filings, regulators' notices and fund reports held on this site. Posts marked 🤖 are written automatically from official data and state no opinion. Member comments are their authors' views, shown after an editor's review; they are not investment advice.